Amneal Pharmaceuticals, Inc.

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-15 pm EDT			5-day change	1st Jan Change
11.93 ^USD	-2.45%		-9.62%	-5.32%

May. 07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17	MT
May. 07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M	MT

Amneal Pharmaceuticals Launches Generic Lumigan Eye Drops

Published on 04/09/2026 at 09:29 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Amneal Pharmaceuticals, Inc.

May. 07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17	MT
May. 07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M	MT
May. 07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.22	MT
May. 07	Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2026	CI
May. 07	Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 22	Amneal Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Kashiv BioSciences, LLC for $1.1 billion.	CI
Apr. 22	Amneal Pharmaceuticals, Inc., Q1 2026 Earnings Call, Apr 22, 2026
Apr. 22	Kashiv Biosciences agrees to be acquired by Amneal Pharmaceuticals to create a fully integrated global biosimilar leader	RE
Apr. 22	Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal	RE
Apr. 22	Amneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal	MT
Apr. 22	(AMRX) Amneal Pharmaceuticals Expects 2026 Revenue Range $3.05B - $3.15B, vs. FactSet Est of $3.1B	MT
Apr. 22	(AMRX) Amneal Pharmaceuticals Expects 2026 Adjusted EPS Range $0.95 - $1.05, vs. FactSet Est of $0.99	MT
Apr. 22	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17	MT
Apr. 22	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M	MT
Apr. 22	Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026	CI

Chart Amneal Pharmaceuticals, Inc.

Duration

Period

AMRX: Dynamic Chart

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinsonâ€™s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Employees

8,700

Sector

Pharmaceuticals

More about the company